In Reply In response to Dr Xu and colleagues, we performed additional analyses to examine the difference in clinical benefit of RAS blockers between Black and White patients (Table). The results were nearly identical to the findings in our main analysis comparing Black and non-Black patients, suggesting the heterogeneity across these patient groups was not substantial, as Xu and colleagues had expected.
